Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Cutting-Edge Diagnostic Tool Rapidly Identifies Emerging SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 11 Nov 2024

As the COVID-19 pandemic continues to evolve, the emergence of new variants of the SARS-CoV-2 virus presents ongoing challenges for public health monitoring and response, despite the rise of vaccinations and herd immunity from previous infections, which have helped reduce severe cases compared to earlier in the pandemic. More...

While traditional methods, such as whole-genome sequencing (WGS), offer high accuracy, they are time-consuming and costly. Researchers have now made a significant advancement in the battle against COVID-19 by developing an innovative diagnostic tool that can quickly identify emerging variants of the SARS-CoV-2 virus. This new system combines advanced DNA detection technology with sophisticated computational algorithms to provide a faster and more affordable method for monitoring viral mutations, a crucial tool for managing future pandemics.

A team of researchers from Kumamoto University (Kumamoto, Japan) developed the novel diagnostic tool, Intelli-OVI, which integrates IntelliPlex micro-disc technology with a groundbreaking algorithm called Objective Variant Identification (OVI). This system offers a faster alternative for detecting and distinguishing over 20 SARS-CoV-2 variants with high accuracy. IntelliPlex technology uses a microdisc that is printed with a unique pictorial pattern (πCode), enabling the system to capture and analyze specific genetic mutations in the virus. This process allows the system to simultaneously handle multiple viral mutations, greatly accelerating detection. The OVI algorithm then interprets the data to identify both known and new variants by analyzing the unique mutation patterns.

In laboratory tests, Intelli-OVI successfully identified over 20 variants, including several subtypes of the Omicron variant, using 35 different DNA probes. Unlike traditional PCR-based methods, which can only detect a limited number of mutations, Intelli-OVI has the theoretical capacity to analyze up to 100 viral mutation sites at once, making it one of the most comprehensive diagnostic tools available. The successful development of Intelli-OVI holds the potential to make a significant contribution to global pandemic preparedness. The research team envisions that this technology could be applied to other rapidly evolving viruses, offering an essential tool for early detection and containment strategies.

"Our system can be easily updated to track new viral mutations," said Professor Yorifumi Satou, the lead researcher from the Joint Research Center for Human Retrovirus Infection (JRCHRI), Kumamoto University. "This new diagnostic tool has the potential to revolutionize how we monitor viral mutations, not just for COVID-19, but for future pandemics as well.”


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.